Combining advanced selective laser trabeculoplasty (SLT) photoregeneration therapy and traditional YAG photodisruption treatments, the Optimis Fusion system offers ophthalmologists a versatile armamentarium for treating both cataract and glaucoma in an efficient combination platform.
Incorporating the most advanced laser technology available, the SLT mode provides a first-choice treatment for managing glaucoma and lowering intraocular pressure.
It works by targeting melanin-rich cells that absorb the laser energy to induce a healing response, improving the function of trabecular meshwork.
Optimis Fusion’s YAG mode delivers high-performance photodisruption for capsulotomy and peripheral iridotomy surgical procedures. The gaussian laser beam profile allows for precise laser delivery at minimum energy levels, avoiding adverse side effects such as lens pitting.
Quantel Medical CEO Jean-Marc Gendre said that the Optimis Fusion has proven to be a very attractive laser platform since introduction earlier 2014 in other markets.
"Driving the acceptance of this product introduction is the ability to combine a 532nm mono spot or multispot retina laser, a unique feature to Quantel’s laser line," Gendre added.
According to Quantel Medical, integrating the Optimis Fusion with its Vitra Monospot and Multispot pattern-scanning retina laser systems offers comprehensive treatment options for multi-specialty practices looking to treat glaucoma, cataract and retina conditions in one laser platform.
